首页> Clinical infectious diseases : an official publication of the Infectious Diseases Society of America> Safety and Efficacy of Triple Therapy With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Human Immunodeficiency Virus Type 2 Patients: Results From a 48-Week Phase 2 Study.

Safety and Efficacy of Triple Therapy With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Human Immunodeficiency Virus Type 2 Patients: Results From a 48-Week Phase 2 Study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Patrícia,Pacheco

第一单位： Infectious Diseases Department, Hospital Professor Doutor Fernando Fonseca, Amadora, Portugal.

作者： Patrícia,Pacheco ^[1] ; Nuno,Marques ^[2] ; Paulo,Rodrigues ^[3] ; Kamal,Mansinho ^[4] ; Fernando,Maltez ^[5] ; Nuno,Janeiro ^[6] ; Cláudia,Franco ^[6] ; Diva,Trigo ^[1] ; Joana,Batista ^[1] ; Luís,Duque ^[1] ; Maria João,Lopes ^[1] ; Maria João,Aleixo ^[2] ; Ana Rita,Silva ^[3] ; Raquel,Tavares ^[3] ; João,Alves ^[4] ; Susana,Peres ^[4] ; Diana,Póvoas ^[5] ; Sara,Lino ^[5] ; Perpétua,Gomes ^[7] ; Vânia,Araújo ^[8] ; Cristina,Lopes ^[8]

作者单位： Infectious Diseases Department, Hospital Professor Doutor Fernando Fonseca, Amadora, Portugal. ^[1] Infectious Diseases Department, Hospital Garcia de Orta, Almada, Portugal. ^[2] Infectious Diseases Department, Hospital Beatriz Ângelo, Loures, Portugal. ^[3] Infectious Diseases Department, Hospital Egas Moniz, Lisboa, Portugal. ^[4] Infectious Diseases Department, Hospital Curry Cabral, Lisboa, Portugal. ^[5] Infectious Diseases Department, Hospital Santa Maria, Lisboa, Portugal. ^[6] Molecular Biology Laboratory, Hospital Egas Moniz, Lisboa, Portugal. ^[7] BlueClinical Ltd, Matosinhos, Portugal. ^[8]

关键词 HIV-2 antiretroviral treatment dolutegravir integrase inhibitor